The objective of this acquisition is to continue a major component of the National Institute on Drug Abuse’s (NIDA) established contracts, the NIDA/Division of Therapeutics and Medical Consequences (DTMC)/Addiction Treatment Discovery Program (ATDP). The program requires in-house capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems, in addition to in vitro predictive toxicology assays.